regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from pharmacy benefit managers. These companies are typically building barriers to access, such as high cost requirements and approval processes that restrict user access. Analy